Bempedoic acid is the first ATP-citrate lyase inhibitor approved for clinical use, and the first oral non-statin to demonstrate cardiovascular outcome benefit in a large randomized trial. It lowers LDL cholesterol by inhibiting ATP-citrate lyase…